ARCHIMED closes MED IV fund at €1.5 billion ($1.75 billion) hard cap, three times oversubscribed, in less than six months of fundraising.

MED IV follows the €650 million ($750 million) MED III fund. It will pursue the series’ smallcap healthcare buyout strategy, while building a more diversified, global portfolio.

 

ARCHIMED, a global private equity specialist exclusively focused on healthcare, announces the final closing of the MED IV fund at its €1.5 billion ($1.75 billion) hard cap. Launched in January 2026 with an original target of €1.2 billion ($1.4 billion), the fund closed in less than six months and was three times oversubscribed, reflecting strong, sustained demand from existing and new investors.

“The momentum behind MED IV reflects investors’ confidence in our approach,” says Denis Ribon, Chairman and Managing Partner at ARCHIMED.  “Investors like our healthcare specialization, top-decile DPI track-record [ratio of distributed to paid-in capital], our proven alpha-focused Playbook, the well-structured and scalable platform, and our transparent governance and stable ownership.”

MED IV’s investor base is global, loyal and expanding. The fund attracted a broad group of largely institutional limited partners, including pension funds, insurance companies and sovereign wealth funds, who believe ARCHIMED will reliably generate superior returns in healthcare. The process of opening ARCHIMED’s Abu Dhabi office in August 2026 further cemented relationships across the Middle East and Asia, contributing to the geographic diversification of the LP base.

Since inception, the smallcap MED fund series has built on a robust performance history. Raising €146 million over 2014 and 2015, MED I, now fully realized, delivered a 7.2x multiple on invested capital and a 59% gross annualized return. Raising €315 million in 2018, MED II (50% realized) already shows a 3.1x MOIC and 33% annualized return (as of Q2 2026). The €650 MED III fund, closed in 2021, is a top quartile performer for its vintage year, as are all ARCHIMED funds, according to data from Preqin.